---
title: "Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289828976.md"
description: "Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years with an annualized return of 21.59%. A $1,000 investment made two decades ago would be worth approximately $49,675 today, highlighting the power of compounded returns."
datetime: "2026-06-15T20:45:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289828976.md)
  - [en](https://longbridge.com/en/news/289828976.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289828976.md)
---

# Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.16% on an annualized basis producing an average annual return of 21.59%. Currently, Regeneron Pharmaceuticals has a market capitalization of $64.32 billion.

**Buying $1000 In REGN:** If an investor had bought $1000 of REGN stock 20 years ago, it would be worth **$49,675.28** today based on a price of $613.48 for REGN at the time of writing.

### Regeneron Pharmaceuticals's Performance Over Last 20 Years

![comp_fig](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1781556328_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN](https://longbridge.com/en/news/293102094.md)
- [Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer | MRK Stock News](https://longbridge.com/en/news/293648797.md)
- [Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS](https://longbridge.com/en/news/293393923.md)
- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Why experts say earnings growth may be stalling—and what that means for stocks](https://longbridge.com/en/news/293789004.md)